Cancer of unknown primary origin other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Other diagnostic studies for cancer of unknown primary that may help establish the origin of the tumor include tumor markers, diagnostic tonsillectomy, and gastrointestinal endoscopy. | Other [[Diagnostic|diagnostic studies]] for cancer of unknown primary that may help establish the origin of the [[tumor]] include [[tumor markers]], diagnostic [[tonsillectomy]], and [[gastrointestinal]] [[endoscopy]]. | ||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
Other diagnostic studies for cancer of unknown primary that may help establish the origin of the tumor include: | Other diagnostic studies for cancer of unknown primary that may help establish the origin of the [[tumor]] include: | ||
*[[Tumor markers]] such as [[Alpha fetoprotein|αFP]], [[Human chorionic gonadotrophin|βHCG]], [[CA125]], CA 27.29, [[CA19-9|CA 19.9]], and [[CEA]]<ref name="pmid22161237">{{cite journal| author=Molina R, Bosch X, Auge JM, Filella X, Escudero JM, Molina V et al.| title=Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. | journal=Tumour Biol | year= 2012 | volume= 33 | issue= 2 | pages= 463-74 | pmid=22161237 | doi=10.1007/s13277-011-0275-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22161237 }} </ref> | *[[Tumor markers]] such as [[Alpha fetoprotein|αFP]], [[Human chorionic gonadotrophin|βHCG]], [[PSA]], [[CA125]], CA 27.29, [[CA19-9|CA 19.9]], and [[CEA]]<ref name="pmid22161237">{{cite journal| author=Molina R, Bosch X, Auge JM, Filella X, Escudero JM, Molina V et al.| title=Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. | journal=Tumour Biol | year= 2012 | volume= 33 | issue= 2 | pages= 463-74 | pmid=22161237 | doi=10.1007/s13277-011-0275-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22161237 }} </ref> | ||
**[[Alpha fetoprotein|αFP]] and [[Human chorionic gonadotrophin|βHCG]] must be tested in patients presenting with midline [[metastatic disease]].<ref name="pmid26314775">{{cite journal| author=Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G et al.| title=Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2015 | volume= 26 Suppl 5 | issue= | pages= v133-8 | pmid=26314775 | doi=10.1093/annonc/mdv305 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26314775 }}</ref> | |||
**[[PSA]] must be tested in patients presenting with adencarcinomatous [[bone metastases]].<ref name="pmid26314775" /> | |||
*Diagnostic [[tonsillectomy]]<ref name="pmid3815873">{{cite journal| author=Tytor M, Olofsson J| title=Cervical lymph node metastases with occult primary. | journal=Clin Otolaryngol Allied Sci | year= 1986 | volume= 11 | issue= 6 | pages= 463-7 | pmid=3815873 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3815873 }} </ref> | *Diagnostic [[tonsillectomy]]<ref name="pmid3815873">{{cite journal| author=Tytor M, Olofsson J| title=Cervical lymph node metastases with occult primary. | journal=Clin Otolaryngol Allied Sci | year= 1986 | volume= 11 | issue= 6 | pages= 463-7 | pmid=3815873 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3815873 }} </ref> | ||
*[[Endoscopy|Gastrointestinal endoscopy]], ENT panendoscopy (which is a combination of [[laryngoscopy]], [[esophagoscopy]], and [[bronchoscopy]]), [[proctoscopy]], and [[colposcopy]]<ref name="pmid1932839">{{cite journal| author=Mousseau M, Schaerer R, Lutz JM, Ménégoz F, Faure H, Swiercz P| title=[Hepatic metastasis of unknown primary site]. | journal=Bull Cancer | year= 1991 | volume= 78 | issue= 8 | pages= 725-36 | pmid=1932839 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1932839 }} </ref><ref name="pmid2221252">{{cite journal| author=Lefebvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A| title=Cervical lymph nodes from an unknown primary tumor in 190 patients. | journal=Am J Surg | year= 1990 | volume= 160 | issue= 4 | pages= 443-6 | pmid=2221252 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2221252 }} </ref> | *[[Endoscopy|Gastrointestinal endoscopy]], ENT panendoscopy (which is a combination of [[laryngoscopy]], [[esophagoscopy]], and [[bronchoscopy]]), [[proctoscopy]], and [[colposcopy]]<ref name="pmid1932839">{{cite journal| author=Mousseau M, Schaerer R, Lutz JM, Ménégoz F, Faure H, Swiercz P| title=[Hepatic metastasis of unknown primary site]. | journal=Bull Cancer | year= 1991 | volume= 78 | issue= 8 | pages= 725-36 | pmid=1932839 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1932839 }} </ref><ref name="pmid2221252">{{cite journal| author=Lefebvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A| title=Cervical lymph nodes from an unknown primary tumor in 190 patients. | journal=Am J Surg | year= 1990 | volume= 160 | issue= 4 | pages= 443-6 | pmid=2221252 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2221252 }} </ref> | ||
*Octreoscan and plasma chromogranin A | |||
**In patients with neuroendocrine tumors | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 22:57, 17 October 2019
|
Cancer of unknown primary origin Microchapters |
|
Differentiating Cancer of Unknown Primary Origin from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cancer of unknown primary origin other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Cancer of unknown primary origin other diagnostic studies |
|
FDA on Cancer of unknown primary origin other diagnostic studies |
|
CDC on Cancer of unknown primary origin other diagnostic studies |
|
Cancer of unknown primary origin other diagnostic studies in the news |
|
Blogs on Cancer of unknown primary origin other diagnostic studies |
|
Risk calculators and risk factors for Cancer of unknown primary origin other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Roukoz A. Karam, M.D.[2]
Overview
Other diagnostic studies for cancer of unknown primary that may help establish the origin of the tumor include tumor markers, diagnostic tonsillectomy, and gastrointestinal endoscopy.
Other Diagnostic Studies
Other diagnostic studies for cancer of unknown primary that may help establish the origin of the tumor include:
- Tumor markers such as αFP, βHCG, PSA, CA125, CA 27.29, CA 19.9, and CEA[1]
- αFP and βHCG must be tested in patients presenting with midline metastatic disease.[2]
- PSA must be tested in patients presenting with adencarcinomatous bone metastases.[2]
- Diagnostic tonsillectomy[3]
- Gastrointestinal endoscopy, ENT panendoscopy (which is a combination of laryngoscopy, esophagoscopy, and bronchoscopy), proctoscopy, and colposcopy[4][5]
- Octreoscan and plasma chromogranin A
- In patients with neuroendocrine tumors
References
- ↑ Molina R, Bosch X, Auge JM, Filella X, Escudero JM, Molina V; et al. (2012). "Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site". Tumour Biol. 33 (2): 463–74. doi:10.1007/s13277-011-0275-1. PMID 22161237.
- ↑ 2.0 2.1 Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G; et al. (2015). "Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 26 Suppl 5: v133–8. doi:10.1093/annonc/mdv305. PMID 26314775.
- ↑ Tytor M, Olofsson J (1986). "Cervical lymph node metastases with occult primary". Clin Otolaryngol Allied Sci. 11 (6): 463–7. PMID 3815873.
- ↑ Mousseau M, Schaerer R, Lutz JM, Ménégoz F, Faure H, Swiercz P (1991). "[Hepatic metastasis of unknown primary site]". Bull Cancer. 78 (8): 725–36. PMID 1932839.
- ↑ Lefebvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A (1990). "Cervical lymph nodes from an unknown primary tumor in 190 patients". Am J Surg. 160 (4): 443–6. PMID 2221252.